The price-to-earnings ratio for Johnson & Johnson (NYSE: JNJ) is above average at 26.59x, Company’s 36-month beta value is 0.52.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 8 as “hold,” and 2 as “sell.”
The public float for JNJ is 2.40B, and currently, short sellers hold a 0.78% ratio of that floaft. The average trading volume of JNJ on October 28, 2024 was 6.34M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
JNJ) stock’s latest price update
Johnson & Johnson (NYSE: JNJ)’s stock price has gone decline by -1.70 in comparison to its previous close of 163.67, however, the company has experienced a -2.57% decrease in its stock price over the last five trading days. fool.com reported 2024-10-26 that These healthcare stocks have fantastic dividend track records.
JNJ’s Market Performance
Johnson & Johnson (JNJ) has seen a -2.57% fall in stock performance for the week, with a -0.32% decline in the past month and a 1.46% surge in the past quarter. The volatility ratio for the week is 1.71%, and the volatility levels for the past 30 days are at 1.33% for JNJ. The simple moving average for the past 20 days is -0.82% for JNJ’s stock, with a 3.03% simple moving average for the past 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with Daiwa Securities repeating the rating for JNJ by listing it as a “Neutral.” The predicted price for JNJ in the upcoming period, according to Daiwa Securities is $150 based on the research report published on July 23, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $160. The rating they have provided for JNJ stocks is “Neutral” according to the report published on May 30th, 2024.
HSBC Securities gave a rating of “Buy” to JNJ, setting the target price at $170 in the report published on April 18th of the current year.
JNJ Trading at -1.47% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.72% of loss for the given period.
Volatility was left at 1.33%, however, over the last 30 days, the volatility rate increased by 1.71%, as shares sank -0.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.13% upper at present.
During the last 5 trading sessions, JNJ fell by -2.57%, which changed the moving average for the period of 200-days by -0.61% in comparison to the 20-day moving average, which settled at $162.21. In addition, Johnson & Johnson saw 2.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Decker Robert J, who sale 5,635 shares at the price of $165.06 back on Aug 30 ’24. After this action, Decker Robert J now owns 18,973 shares of Johnson & Johnson, valued at $930,113 using the latest closing price.
Decker Robert J, the Officer of Johnson & Johnson, proposed sale 5,635 shares at $165.06 during a trade that took place back on Aug 30 ’24, which means that Decker Robert J is holding shares at $930,113 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.69 for the gross margin
The net margin for Johnson & Johnson stands at 0.17. Equity return is now at value 20.89, with 8.58 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 4.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
In a nutshell, Johnson & Johnson (JNJ) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
